Veryan appoints Nick Yeo as chief operating officer

128

Veryan, a company specialised in vascular disease treatment, has announced the appointment of Nick Yeo as chief operating officer.

Nick has over 20 years of international experience in the healthcare industry. He began his career in pharmaceuticals, becoming CEO of Sterling Winthrop Prescription Medicines, before moving on to senior marketing and business leadership roles at Gensia Europe and Scotia QuantaNova. Before joining Veryan he held senior management positions in product and clinical development at oncology drug-device specialist Light Sciences, where he led the formation of a cardiovascular technology startup.


“We are delighted that Nick has joined us at such an exciting stage of the company’s development,” commented Chas Taylor, chief executive, Veryan. “His specific expertise will prove particularly valuable as we gear up towards a regulatory submission in Europe for our BioMimics 3D stent”.